Celcuity Inc.
corporate_fare Company Profile
Celcuity Inc. (NASDAQ:CELC) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 38 items for CELC at importance 7 or higher on its 1–10 market-impact scale.
Recent high-impact activity:
- Celcuity Announces Preliminary $400M Convertible Senior Notes Offering to Repay Secured Debt and Fund Operations
- Celcuity Shares Plunge 25% as Breast Cancer Drug Data Disappoints Investors
- Celcuity's Gedatolisib Doubles PFS to 11.3 Months in Breast Cancer Trial
- Celcuity's Gedatolisib Shows Superior Efficacy in Phase 3 Breast Cancer Trial
- Stockholders Approve New Equity Incentive Plan and Expanded ESPP
Financial Snapshot
Fiscal year ended December 31, 2025
Net Income
-$177.04M
Diluted EPS
-$3.79
Op. Cash Flow
-$153.28M
Free Cash Flow
-$153.53M
Operating Income
-$172.19M
Cash & Equivalents
$165.7M
Total Debt
$195.32M
Debt / Equity
1.94×
Shares Outstanding
48.24M sh
Source: 10-K · filed 2026-03-26 · accession 0001493152-26-012801
show_chartPrice Chart
Loading chart...
feed CELC - Filings & News (Page 2)
CELC
Jun 03, 2026, 7:16 AM EDT
Price at Filing:
$93.85
Real-time Price:
$53.35
Change:
-$40.50 (-43%)
Market Cap:
$2.621B
CELC
Jun 02, 2026, 1:17 PM EDT
Price at Filing:
$92.00
Real-time Price:
$53.35
Change:
-$38.65 (-42%)
Market Cap:
$2.621B
CELC
Jun 02, 2026, 8:13 AM EDT
Price at Filing:
$92.00
Real-time Price:
$53.35
Change:
-$38.65 (-42%)
Market Cap:
$2.621B
CELC
Jun 02, 2026, 8:10 AM EDT
Price at Filing:
$91.98
Real-time Price:
$53.35
Change:
-$38.63 (-42%)
Market Cap:
$2.621B
CELC
May 18, 2026, 4:05 PM EDT
Price at Filing:
$132.18
Real-time Price:
$53.35
Change:
-$78.83 (-60%)
Market Cap:
$2.621B
CELC
May 14, 2026, 5:15 PM EDT
Price at Filing:
$138.87
Real-time Price:
$53.35
Change:
-$85.52 (-62%)
Market Cap:
$2.621B
CELC
May 14, 2026, 4:11 PM EDT
Price at Filing:
$129.58
Real-time Price:
$53.35
Change:
-$76.23 (-59%)
Market Cap:
$2.621B
CELC
May 14, 2026, 4:05 PM EDT
Price at Filing:
$129.58
Real-time Price:
$53.35
Change:
-$76.23 (-59%)
Market Cap:
$2.621B
CELC
May 14, 2026, 11:45 AM EDT
Celcuity Expands Phase 3 Breast Cancer Trial for Gedatolisib to Include Endocrine-Sensitive Patients
Price at Filing:
$133.47
Real-time Price:
$53.35
Change:
-$80.12 (-60%)
Market Cap:
$2.621B
CELC
May 14, 2026, 7:35 AM EDT
Price at Filing:
$127.30
Real-time Price:
$53.35
Change:
-$73.95 (-58%)
Market Cap:
$2.621B
CELC
May 01, 2026, 5:10 PM EDT
Price at Filing:
$140.00
Real-time Price:
$53.35
Change:
-$86.65 (-62%)
Market Cap:
$2.621B
CELC
May 01, 2026, 5:03 PM EDT
Price at Filing:
$125.65
Real-time Price:
$53.35
Change:
-$72.30 (-58%)
Market Cap:
$2.621B
CELC
Mar 26, 2026, 7:30 AM EDT
Price at Filing:
$108.00
Real-time Price:
$53.35
Change:
-$54.65 (-51%)
Market Cap:
$2.621B
CELC
Mar 25, 2026, 4:13 PM EDT
Price at Filing:
$106.01
Real-time Price:
$53.35
Change:
-$52.66 (-50%)
Market Cap:
$2.621B
CELC
Mar 25, 2026, 4:10 PM EDT
Price at Filing:
$106.01
Real-time Price:
$53.35
Change:
-$52.66 (-50%)
Market Cap:
$2.621B
CELC
Mar 24, 2026, 4:06 PM EDT
Price at Filing:
$102.01
Real-time Price:
$53.35
Change:
-$48.66 (-48%)
Market Cap:
$2.621B
CELC
Feb 12, 2026, 4:30 PM EST
Price at Filing:
$104.87
Real-time Price:
$53.35
Change:
-$51.52 (-49%)
Market Cap:
$2.621B
CELC
Jan 09, 2026, 4:30 PM EST
Price at Filing:
$107.51
Real-time Price:
$53.35
Change:
-$54.16 (-50%)
Market Cap:
$2.621B